In the US, Brethine (terbutaline systemic) is a member of the following drug classes: adrenergic bronchodilators, tocolytic agents and is used to treat Asthma - acute, Asthma - Maintenance and Premature Labor.
US matches:
Terbutaline sulfate (a derivative of Terbutaline) is reported as an ingredient of Brethine in the following countries:
International Drug Name Search
Rubidexol may be available in the countries listed below.
Methadone hydrochloride (a derivative of Methadone) is reported as an ingredient of Rubidexol in the following countries:
International Drug Name Search
Lafol may be available in the countries listed below.
Folic Acid is reported as an ingredient of Lafol in the following countries:
International Drug Name Search
Novopulm Novolizer may be available in the countries listed below.
Budesonide is reported as an ingredient of Novopulm Novolizer in the following countries:
International Drug Name Search
Raserpamil may be available in the countries listed below.
Verapamil is reported as an ingredient of Raserpamil in the following countries:
International Drug Name Search
Reminal may be available in the countries listed below.
Enalapril is reported as an ingredient of Reminal in the following countries:
International Drug Name Search
Noreskin may be available in the countries listed below.
Azelaic Acid is reported as an ingredient of Noreskin in the following countries:
International Drug Name Search
Lorazepam Hexal may be available in the countries listed below.
Lorazepam is reported as an ingredient of Lorazepam Hexal in the following countries:
International Drug Name Search
Class: Angiotensin II Receptor Antagonists
VA Class: CV805
Chemical Name: Cyclic 2,3 carbonate 2,3 - dihydroxy - 2 - butenyl - 4 - (1 - hydroxy - 1 - methylethyl) - 1 - propyl - 1 - [p - (o - 1H - tetrazol - 5 - ylphenyl)benzyl]imidazole - 5 - carboxylate
Molecular Formula: C29H30N6O6
CAS Number: 144689-63-4
Brands: Azor (combination), Benicar, Benicar HCT
May cause fetal and neonatal morbidity and mortality if used during pregnancy.1 31 42 43 44 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
If pregnancy is detected, discontinue the drug as soon as possible.1 31 43 44
Olmesartan is an angiotensin II type 1 (AT1) receptor antagonist.1 2 3 16 28 31 44
Olmesartan is used for management of hypertension (alone or in combination with other classes of antihypertensive agents);1 2 3 8 9 28 31 44 may be used in fixed combination with amlodipine or hydrochlorothiazide when such combined therapy is indicated.31 44
Angiotensin II receptor antagonists are one of several preferred initial therapies in hypertensive patients with chronic kidney disease, diabetes mellitus, or heart failure.30
Angiotensin II receptor antagonists can be used as monotherapy for initial management of uncomplicated hypertension; however, thiazide diuretics are preferred by JNC 7.30
Angiotensin II receptor antagonists or ACE inhibitors are first-line agents in the treatment of diabetic nephropathy† in patients with type 2 diabetes mellitus and hypertension.
Angiotensin II receptor antagonists are second-line agents in the treatment of CHF†; should be used only in those intolerant of ACE inhibitors.
Fixed-combination olmesartan/amlodipine and olmesartan/hydrochlorothiazide tablets should not be used for initial treatment of hypertension.31 44
Administer olmesartan orally once daily without regard to meals.1 2
Olmesartan is available as olmesartan medoxomil; dosage expressed in terms of the salt.1 31 44
Initially, olmesartan medoxomil 20 mg once daily in adults without intravascular volume depletion.1 Adjust dosage at approximately monthly intervals (more aggressively in high-risk patients) to achieve BP control.4 30
Usual olmesartan medoxomil dosage: 20–40 mg once daily; no additional therapeutic benefit with higher dosages1 30 or with twice-daily dosing.1 28
If BP is not adequately controlled by monotherapy with olmesartan (or another angiotensin II receptor antagonist) or amlodipine (or another dihydropyridine-derivative calcium-channel blocker), can switch to the fixed-combination preparation containing olmesartan medoxomil 20 mg and amlodipine 5 or 10 mg or, alternatively, olmesartan medoxomil 40 mg and amlodipine 5 or 10 mg.44
Can use the fixed combination as a substitute for the individually titrated drugs.44 Can switch to the fixed-combination preparation containing the corresponding individual doses of olmesartan and amlodipine; alternatively, can increase the dosage of one or both components for additional antihypertensive effects.44
Adjust dosage of olmesartan/amlodipine fixed combination, up to a maximum dosage of olmesartan medoxomil 40 mg and amlodipine 10 mg daily, according to patient’s response after ≥2 weeks at the current dosage.44
If BP is not adequately controlled by monotherapy with olmesartan or hydrochlorothiazide, can switch to fixed-combination olmesartan/hydrochlorothiazide tablets.31 In patients already receiving olmesartan, initiate hydrochlorothiazide at dosage of 12.5 mg once daily; in those receiving hydrochlorothiazide, consider reducing hydrochlorothiazide dosage to 12.5 mg and initiate olmesartan medoxomil at dosage of 20 mg once daily.31 Increase dosages to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg once daily, if needed, to control BP.31
If BP is controlled with olmesartan and hydrochlorothiazide (administered separately), can switch to the fixed-combination preparation containing the corresponding individual doses for convenience.31
Adjust dosage of olmesartan/hydrochlorothiazide fixed combination according to patient’s response after 2–4 weeks at the current dosage.31
The following information addresses dosage of olmesartan in special populations. Dosages of drugs administered in fixed combination with olmesartan also may require adjustment in certain patient populations; the need for such dosage adjustments must be considered in the context of cautions, precautions, and contraindications specific to that population and drug.31 44
No adjustment of initial olmesartan dosage necessary in patients with moderate to severe hepatic impairment.1 31
Amount of amlodipine in olmesartan/amlodipine fixed combinations exceeds the recommended initial dosage of amlodipine (2.5 mg daily) in patients with hepatic impairment.44
Manufacturer states that no adjustment of initial olmesartan dosage is necessary in patients with moderate to severe renal impairment (Clcr <40 mL/minute).1 31 44 However, some clinicians recommend lower initial dosage in patients with Clcr <20 mL/minute, with maximum dosage of 20 mg once daily in such patients.10
Dosage of olmesartan in patients with end-stage renal disease not determined.29
Olmesartan/hydrochlorothiazide fixed combination not recommended in patients with severe renal impairment (Clcr ≤30 mL/minute).31 Loop diuretics are preferred to thiazides in these patients.31
No adjustment of initial olmesartan dosage is necessary.1 31
Amount of amlodipine in olmesartan/amlodipine fixed combinations exceeds the recommended initial dosage of amlodipine (2.5 mg daily) in patients ≥75 years of age.44
Correct volume and/or salt depletion prior to initiation of olmesartan therapy or initiate therapy under close medical supervision using lower initial dosage.1 31 44
Known hypersensitivity to olmesartan or any ingredient in the formulation.1 31
When olmesartan is used in fixed combination with hydrochlorothiazide or amlodipine, consider contraindications associated with the concomitant agent.31 41
Possible symptomatic hypotension with olmesartan, particularly in volume- and/or salt-depleted patients (e.g., those treated with diuretics).1 31 44 (See Volume- and/or Salt-Depleted Patients under Dosage and Administration.)
Transient hypotension is not a contraindication to additional doses; may reinstate olmesartan therapy cautiously after BP is stabilized (e.g., with volume expansion).1 31 44
Results of 2 randomized controlled trials in patients with type 2 diabetes mellitus showed an increased risk of death from cardiovascular causes (e.g., MI, sudden death, stroke) in patients receiving olmesartan compared with placebo.124 FDA is continuing to evaluate the data and has not concluded that the drug increases risk of cardiovascular death.124 Numerous controlled studies have evaluated olmesartan and other angiotensin II receptor antagonists in patients at high risk of cardiovascular events and have not suggested an increased risk of cardiovascular mortality.124 Because benefits of olmesartan in hypertensive patients continue to outweigh potential risks, FDA states that patients should continue to take the drug as prescribed unless otherwise instructed by a clinician.124
Possible fetal and neonatal morbidity and mortality when drugs that act directly on the renin-angiotensin system (e.g., angiotensin II receptor antagonists, ACE inhibitors) are used during the second and third trimesters of pregnancy.1 4 31 43 44 (See Boxed Warning.) ACE inhibitors also may increase the risk of major congenital malformations when administered during the first trimester of pregnancy.42 43
Discontinue olmesartan as soon as possible when pregnancy is detected, unless continued use is considered lifesaving.1 31 42 43 44 Nearly all women can be transferred successfully to alternative therapy for the remainder of their pregnancy.13
In July 2010, FDA initiated a safety review of angiotensin II receptor antagonists after a published meta-analysis found a modest but statistically significant increase in risk of new cancer occurrence in patients receiving an angiotensin II receptor antagonist compared with control.120 121 123 126 However, subsequent studies, including a larger meta-analysis conducted by FDA, have not shown such risk.126 127 128 129 Based on currently available data, FDA has concluded that angiotensin II receptor antagonists do not increase the risk of cancer.126
Anaphylactoid reactions and/or angioedema possible with angiotensin II receptor antagonists;1 2 7 14 extreme caution in patients with a history of angioedema associated with or unrelated to ACE inhibitor or angiotensin II receptor antagonist therapy.7 15 45
When olmesartan is used in fixed combination with amlodipine or hydrochlorothiazide, consider cautions, precautions, contraindications, and interactions associated with the concomitant agent.31 44 Consider cautionary information applicable to specific populations (e.g., pregnant or nursing women, individuals with hepatic or renal impairment, geriatric patients) for each drug in the fixed combination.31 44
Possible oliguria, progressive azotemia and, rarely, acute renal failure and/or death in patients with severe CHF.1 31 44
Increases in BUN and Scr possible in patients with unilateral or bilateral renal artery stenosis.1 31 44
Olmesartan: Category C (1st trimester); Category D (2nd and 3rd trimesters).1 31 44 (See Boxed Warning.)
Olmesartan is distributed into milk in rats; not known whether olmesartan is distributed into human milk.1 31 44 Discontinue nursing or the drug.1 31 44
Safety and efficacy of olmesartan alone or in fixed combination with amlodipine or hydrochlorothiazide not established.1 31 44
No substantial differences in safety or efficacy of olmesartan alone or in fixed combination with amlodipine relative to younger adults, but increased sensitivity cannot be ruled out.1 44
Insufficient experience with olmesartan given in fixed combination with hydrochlorothiazide in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; select dosage with caution.31
Systemic exposure to olmesartan may be increased.1 31 44 (See Special Populations under Absorption, in Pharmacokinetics.)
Systemic exposure to olmesartan may be increased.1 31 44 (See Special Populations under Absorption, in Pharmacokinetics.) Some clinicians recommend initial dosage adjustment in patients with severe renal impairment.10 (See Renal Impairment under Dosage and Administration.)
Use of olmesartan in fixed combination with hydrochlorothiazide is not recommended in patients with Clcr ≤30 mL/minute.31
Deterioration of renal function may occur.1 31 44 (See Renal Effects under Cautions.)
BP reduction with olmesartan may be smaller in black patients compared with nonblack patients; use in combination with a diuretic.1 5 30 31
Olmesartan: Dizziness,1 2 3 back pain,1 bronchitis,1 2 12 diarrhea1 , headache,1 2 3 12 hematuria,1 hyperglycemia,1 hypertriglyceridemia,1 influenza-like symptoms,1 2 12 pharyngitis,1 rhinitis,1 sinusitis,1 upper respiratory tract infection.2 3 12
The following information addresses potential interactions with olmesartan. When olmesartan is used in fixed combination with hydrochlorothiazide or amlodipine, consider interactions associated with the concomitant agent.31 44
Olmesartan is not metabolized by and does not inhibit or induce CYP isoenzymes.1 2
Drug | Interaction |
|---|---|
Antacids | Pharmacokinetic interactions unlikely1 2 28 |
Digoxin | Pharmacokinetic interactions unlikely1 2 28 |
Hydrochlorothiazide | Pharmacokinetic interactions unlikely1 2 28 Additive hypotensive effects1 31 |
Warfarin | Pharmacokinetic interaction unlikely1 2 28 |
Olmesartan medoxomil (prodrug) is rapidly and completely hydrolyzed to olmesartan during absorption in the GI tract.1 31 44
Absolute bioavailability of olmesartan is about 26%.1 31 44
Peak plasma olmesartan concentration generally reached 1–2 hours following oral administration.1 31 44
Antihypertensive effect of olmesartan is evident within 2 weeks, with maximum BP reduction after 4–6 weeks.1 3
Food does not affect bioavailability of olmesartan.1 31 44
In patients with moderate hepatic impairment, peak plasma concentration of olmesartan is increased; AUC increased by about 60%.1 31 44
In patients with severe renal impairment (Clcr <20 mL/minute), plasma concentrations and AUC of olmesartan are increased.1 31 44 After repeated dosing, AUC values are approximately triple those in patients with normal renal function.1 31 44
In women, peak plasma concentration and AUC of olmesartan are about 10–15% higher than values in men.1 31 44
Olmesartan crosses the placenta and is distributed in the fetus in animals.1 31 44
Olmesartan crosses the blood-brain barrier poorly, if at all, in animals.1 31 44
Olmesartan is distributed into milk in rats; not known whether olmesartan is distributed into human milk.1 31 44
Olmesartan: 99%.1 31 44
Olmesartan medoxomil undergoes rapid and complete ester hydrolysis to olmesartan.1 2 28 31 44 Virtually no further metabolism of olmesartan occurs; not metabolized by CYP isoenzymes.1 2 28 31 44
Olmesartan is eliminated mainly in urine (35–50%) and feces (via bile).1 2 31 44
Biphasic; terminal half-life of olmesartan is approximately 13 hours.1 31 44
In geriatric patients, renal clearance of olmesartan is decreased by approximately 30%.1 31 44
Olmesartan or olmesartan/hydrochlorothiazide fixed combination: 20–25°C.1 31
Olmesartan/amlodipine fixed combination: 25ºC (may be exposed to 15–30ºC).44
Olmesartan medoxomil (prodrug) has little pharmacologic activity until hydrolyzed to olmesartan during absorption.1 2 31 44
Olmesartan blocks the physiologic actions of angiotensin II, including vasoconstrictor and aldosterone-secreting effects.1 31 44
Olmesartan does not interfere with response to bradykinins and substance P.1 31 44
Olmesartan does not share the ACE inhibitor common adverse effect of dry cough.1
When olmesartan is used in fixed combination with hydrochlorothiazide or amlodipine, importance of advising patients of important precautionary information about the concomitant agent.31 44
Risks of use during pregnancy.1 31 42 43 44
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1 31 44
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1 31 44
Importance of informing patients of other important precautionary information.1 31 44 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets, film-coated | 5 mg | Benicar | Daiichi-Sankyo |
20 mg | Benicar | Daiichi-Sankyo | ||
40 mg | Benicar | Daiichi-Sankyo |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets | 20 mg with Amlodipine Besylate 5 mg (of amlodipine) | Azor | Daiichi-Sankyo |
20 mg with Amlodipine Besylate 10 mg (of amlodipine) | Azor | Daiichi-Sankyo | ||
40 mg with Amlodipine Besylate 5 mg (of amlodipine) | Azor | Daiichi-Sankyo | ||
40 mg with Amlodipine Besylate 10 mg (of amlodipine) | Azor | Daiichi-Sankyo | ||
Tablets, film-coated | 20 mg with Hydrochlorothiazide 12.5 mg | Benicar HCT | Daiichi-Sankyo | |
40 mg with Hydrochlorothiazide 12.5 mg | Benicar HCT | Daiichi-Sankyo | ||
40 mg with Hydrochlorothiazide 25 mg | Benicar HCT | Daiichi-Sankyo |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 01/2012. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Azor 10-20MG Tablets (SANKYO): 30/$117.76 or 90/$340.05
Azor 10-40MG Tablets (SANKYO): 90/$442.99 or 270/$1,298.97
Azor 5-20MG Tablets (SANKYO): 30/$121.06 or 90/$349.97
Azor 5-40MG Tablets (SANKYO): 30/$154.35 or 90/$450.93
Benicar 20MG Tablets (SANKYO): 30/$93.99 or 90/$270.96
Benicar 40MG Tablets (SANKYO): 30/$128.99 or 90/$371.99
Benicar 5MG Tablets (SANKYO): 30/$77.99 or 90/$225.97
Benicar HCT 20-12.5MG Tablets (SANKYO): 30/$96.99 or 90/$275.96
Benicar HCT 40-12.5MG Tablets (SANKYO): 30/$131.00 or 90/$375.96
Benicar HCT 40-25MG Tablets (SANKYO): 30/$131.00 or 90/$360.98
Tribenzor 20-5-12.5MG Tablets (SANKYO): 30/$118.74 or 90/$330.31
Tribenzor 40-10-25MG Tablets (SANKYO): 30/$152.14 or 90/$433.29
Tribenzor 40-5-12.5MG Tablets (SANKYO): 30/$152.14 or 60/$304.27
Tribenzor 40-5-25MG Tablets (SANKYO): 30/$154.49 or 90/$444.01
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2012, Selected Revisions December 23, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. Daiichi Sankyo, Inc. Benicar (olmesartan medoxomil) tablets prescribing information. Parsippany, NJ; 2007 Jul.
2. Song JC, White CM. Olmesartan medoxomil (CS-866): an angiotensin II receptor blocker for treatment of hypertension. Formulary. 2001; 36:487-99.
3. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001; 87(Suppl):37-43C.
4. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98?4080.)
5. Anon. Drugs for hypertension. Med Lett Drugs Ther. 2001; 43:17-22. [PubMed 11242494]
6. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9-38A.
7. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother. 2000; 34:526-8. [IDIS 443518] [PubMed 10772441]
8. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001; 3:283-91, 318. [PubMed 11588406]
9. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens. 2001; 19(Suppl 1):S49-56.
10. von Bergmann K, Laeis P, Puchler K et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens. 2001; 19(Suppl 1):S33-40.
11. Walser M. Angiotensin-Receptor Blockers, Type 2 Diabetes, and Renoprotection. N Engl J Med. 2002; 346:706.
12. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens. 2001; 19(Suppl 1):S41-8.
13. US Food and Drug Administration. Dangers of ACE inhibitors during second and third trimesters of pregnancy. FDA Med Bull. 1992; 22:2.
14. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Safety. 1999; 21:23-33. [PubMed 10433351]
15. Kirk JK. Therapy with angiotensin II receptor antagonists. Clin Geriatrics. From the MultiMedia Health Care website.
16. Sankyo Pharma, New York, NY: Personal communication.
17. AstraZeneca, Wayne, PA: personal communication on Candesartan 24:32.08.
18. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2002; 25(Suppl 1):S71-73.
19. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345:861-9. [IDIS 469607] [PubMed 11565518]
20. Lewis EJ, Hunsicker LG, Claarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345:851-60. [IDIS 469606] [PubMed 11565517]
21. DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT-the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002; 4:52-7. [PubMed 11821641]
22. Parving HH, Brenner BM, Cooper ME et al. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy.] (Danish; with English abstract.) Ugeskr Laeger. 2001; 163:5514-9.
23. Weekers L, Krzesinski JM. [Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of IDNT and RENAAL trials.] (French with English abstract.) Rev Med Liege. 2001; 56:723-6.
24. Parving HH, Lehnert H, Brochner-Mortensen J et al and the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345:870-8. [IDIS 469608] [PubMed 11565519]
25. Walser M. Angiotensin-Receptor Blockers, Type 2 Diabetes, and Renoprotection. N Engl J Med. 2002; 346:706.
26. Unger T. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? Am J Cardiol. 1999; 84:9-15S.
27. Martineau P, Goulet J. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure. Ann Pharmacother. 2001; 35:71-84. [IDIS 457649] [PubMed 11197588]
28. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs. 2002; 62:1345-53. [PubMed 12076183]
29. Sankyo Pharma, New York, NY: Personal communication.
30. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) Express. Bethesda, MD: May 14 2003. From NIH website. (Also published in JAMA. 2003; 289.
31. Daiichi Sankyo, Inc. Benicar HCT (olmesartan medoxomil and hydrochlorothiazide) tablets prescribing information. Parsippany, NJ; 2007 Jul.
32. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-83. [IDIS 309043] [PubMed 8422206]
33. Joint National Committee on Detection, Evaluation. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984; 144:1045-57. [IDIS 184763] [PubMed 6143542]
34. Joint National Committee on Detection, Evaluation. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38. [IDIS 242588] [PubMed 3365073]
35. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. [IDIS 490723] [PubMed 12479770]
36. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. [IDIS 490721] [PubMed 12479763]
37. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. [PubMed 10818056]
38. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. [PubMed 10818055]
39. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. [IDIS 452007] [PubMed 10977801]
40. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(Suppl 1):S80-2.
41. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension. 2003; 21:1011-53.
42. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354:2443-51. [PubMed 16760444]
43. Food and Drug Administration. FDA public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. From FDA website.
44. Daiichi Sankyo, Inc. Azor (amlodipine and olmesartan medoxomil) tablets prescribing information. Parsippany, NJ; 2008 Oct.
45. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf. 2002; 25:73-6.
120. Food and Drug Administration. FDA drug safety communication: ongoing safety review of the angiotensin receptor blockers and cancer. Rockville, MD; 2010 Jul 15. From FDA website ().
121. Sipahi I, Debanne SM, Rowland DY et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11:627-36. [PubMed 20542468]
122. Nissen SE. Angiotensin-receptor blockers and cancer: urgent regulatory review needed. Lancet Oncol. 2010; 11:605-6. [PubMed 20542469]
123. Sica DA. Angiotensin receptor blockers and the risk of malignancy: a note of caution. Drug Saf. 2010; 33:709-12. [PubMed 20701404]
124. Food and Drug Administration. FDA drug safety communication: ongoing safety review of Benicar and cardiovascular events. Rockville, MD; 2010 June 11. From FDA website ().
125. Imai E, Ito S, Haneda M et al. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design. Hypertens Res. 2006; 29:703-9. [PubMed 17249526]
126. Food and Drug Administration. FDA drug safety communication: No increase in risk of cancer with certain blood pressure drugs-angiotensin receptor blockers (ARBs). Rockville, MD; 2011 Jun 2. Available from FDA website. Accessed 2011 Jun 15.
127. Bangalore S, Kumar S, Kjeldsen SE et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011; 12:65-82. [PubMed 21123111]
128. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011; 29:623-35. [PubMed 21358417]
129. Pasternak B, Svanström H, Callréus T et al. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011; 123:1729-36. [PubMed 21482967]
130. Volpe M, Morganti A. 2010 Position Paper of the Italian Society of Hypertension (SIIA): Angiotensin Receptor Blockers and Risk of Cancer. High Blood Press Cardiovasc Prev. 2011; 18:37-40. [PubMed 21612311]
131. Siragy HM. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag. 2011; 7:297-313. [PubMed 21633727]
132. Haller H, Viberti GC, Mimran A et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006; 24:403-8. [PubMed 16508590]
In some countries, this medicine may only be approved for veterinary use.
Bacitracin methylene disalicylate (a derivative of Bacitracin) is reported as an ingredient of Robenz in the following countries:
Bacitracin zinc salt (a derivative of Bacitracin) is reported as an ingredient of Robenz in the following countries:
Chlortetracycline calcium salt (a derivative of Chlortetracycline) is reported as an ingredient of Robenz in the following countries:
Lincomycin hydrochloride monohydrate (a derivative of Lincomycin) is reported as an ingredient of Robenz in the following countries:
Oxytetracycline is reported as an ingredient of Robenz in the following countries:
Robenidine hydrochloride (a derivative of Robenidine) is reported as an ingredient of Robenz in the following countries:
Roxarsone is reported as an ingredient of Robenz in the following countries:
International Drug Name Search
Hierro Lafedar may be available in the countries listed below.
Ferrous Fumarate is reported as an ingredient of Hierro Lafedar in the following countries:
Ferrous Sulfate is reported as an ingredient of Hierro Lafedar in the following countries:
International Drug Name Search
